688185:SSECanSino Biologics, Inc. Class A Analysis

CanSino Biologics is trading at CNY 51.41, well above its DCF fair value of under CNY 9 and far above the 20‑day (57.0), 50‑day (62.7) and 200‑day (70.1) SMAs, indicating a sharp technical disconnect. Momentum indicators are weak – RSI sits at 32.7, MACD is bearish with the line below the signal, and volume is on a decreasing trend, all pointing to continued short‑term pressure near the support level of CNY 48.89. Fundamentally, the company shows strong revenue growth (38.7% YoY) but suffers from negative operating and profit margins, a massive PE of 467× versus an industry average of 24.8×, and a high debt‑to‑equity ratio (>23x), suggesting severe overvaluation and cash‑flow strain. The sector faces high regulatory scrutiny and the Chinese geographic exposure adds medium‑level political risk, while the stock’s beta of 0.47 and 30‑day volatility of ~47% imply heightened price swings despite modest market correlation.